文献速递脊柱关节炎

司库奇尤单抗治疗强直性脊柱炎2年临床与影像学结果:MEASURE 1研究

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
PubMed 文献 · Ann Rheum Dis · 2016-12-13

MEASURE 1 III期随机对照研究评估司库奇尤单抗治疗强直性脊柱炎患者2年的临床与影像学效果。第104周时,静脉150mg和75mg组ASAS20应答率分别为73.7%和68.0%,最初随机分配至司库奇尤单抗且X线可评估的患者mSASSS平均变化为0.30±2.53。研究认为司库奇尤单抗可改善症状体征且安全性无意外,脊柱影像学进展均值较低,但需更长期对照研究证实。

要点

  • 司库奇尤单抗治疗104周ASAS20应答率在150mg组为73.7%,75mg组为68.0%。
  • 最初随机分配至司库奇尤单抗且X线可评估者mSASSS平均变化为0.30±2.53。
  • 严重不良事件发生率150mg组12.2%,75mg组13.4%,无意外安全性发现。

核心结论

  • 司库奇尤单抗可改善强直性脊柱炎患者2年的症状体征,且未发现意外安全性问题。
  • 研究数据提示脊柱影像学进展均值较低,但需更长期对照研究确认。

研究设计与样本

  • MEASURE 1为III期随机对照研究,患者随机接受静脉司库奇尤单抗10mg/kg(基线、第2周、第4周)后皮下150mg(n=125)或75mg(n=124)每4周,或安慰剂(n=122)。
  • 安慰剂组从第16周起重新随机接受皮下司库奇尤单抗150mg或75mg。

主要发现

  • 静脉150mg组97例(77.6%)和静脉75mg组103例(83.1%)完成第104周。
  • 全分析集意向治疗中,第104周ASAS20应答率在静脉150mg组为73.7%,静脉75mg组为68.0%。
  • 最初随机分配至司库奇尤单抗且X线可评估的患者(n=168)从基线至第104周mSASSS平均变化为0.30±2.53。
  • 严重不良事件在150mg组报告于12.2%患者,在75mg组报告于13.4%患者。

关键数值与推荐

  • 临床疗效评估包括至第104周的ASAS20应答率。
  • 影像学变化采用改良Stoke强直性脊柱炎脊柱评分(mSASSS)评估第104周变化。

临床怎么用

  • 司库奇尤单抗可用于强直性脊柱炎的2年治疗,临床应答与影像学进展数据可供治疗决策参考。
  • 治疗期间需关注严重不良事件,本研究中150mg组和75mg组发生率分别为12.2%和13.4%。

局限性

  • 脊柱影像学进展均值较低的结果需更长期对照研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS). METHODS: In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122). Placebo-treated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16. Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104. Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). RESULTS: 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104. In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively. Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53. Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively. CONCLUSIONS: Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings. Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies. TRIAL REGISTRATION NUMBER: NCT01358175.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2016. PMID: 27965257. doi:10.1136/annrheumdis-2016-209730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。